AU2003238822A1 - Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof - Google Patents

Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Info

Publication number
AU2003238822A1
AU2003238822A1 AU2003238822A AU2003238822A AU2003238822A1 AU 2003238822 A1 AU2003238822 A1 AU 2003238822A1 AU 2003238822 A AU2003238822 A AU 2003238822A AU 2003238822 A AU2003238822 A AU 2003238822A AU 2003238822 A1 AU2003238822 A1 AU 2003238822A1
Authority
AU
Australia
Prior art keywords
precursors
inhibitors
xanthine phosphodiesterase
preparing xanthine
preparing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2003238822A
Other languages
English (en)
Inventor
Vilas H. Dahanukar
Hoa N. Nguyen
Cecilia A. Orr
Ilia A. Zavialov
Fucheng Zhang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of AU2003238822A1 publication Critical patent/AU2003238822A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
    • C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
    • C07C257/12—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to hydrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AU2003238822A 2002-05-31 2003-05-30 Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof Abandoned AU2003238822A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US38447802P 2002-05-31 2002-05-31
US60/384,478 2002-05-31
PCT/US2003/017042 WO2003101992A1 (en) 2002-05-31 2003-05-30 Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Publications (1)

Publication Number Publication Date
AU2003238822A1 true AU2003238822A1 (en) 2003-12-19

Family

ID=29712039

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2003238822A Abandoned AU2003238822A1 (en) 2002-05-31 2003-05-30 Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof

Country Status (17)

Country Link
US (2) US7074923B2 (US07786301-20100831-C00009.png)
EP (1) EP1509525B9 (US07786301-20100831-C00009.png)
JP (1) JP2005529934A (US07786301-20100831-C00009.png)
CN (2) CN100497336C (US07786301-20100831-C00009.png)
AR (1) AR040232A1 (US07786301-20100831-C00009.png)
AT (1) ATE336494T1 (US07786301-20100831-C00009.png)
AU (1) AU2003238822A1 (US07786301-20100831-C00009.png)
CA (1) CA2483923A1 (US07786301-20100831-C00009.png)
CY (1) CY1105774T1 (US07786301-20100831-C00009.png)
DE (1) DE60307628T2 (US07786301-20100831-C00009.png)
DK (1) DK1509525T5 (US07786301-20100831-C00009.png)
ES (1) ES2270047T3 (US07786301-20100831-C00009.png)
HK (1) HK1068139A1 (US07786301-20100831-C00009.png)
MX (1) MXPA04011862A (US07786301-20100831-C00009.png)
PT (1) PT1509525E (US07786301-20100831-C00009.png)
WO (1) WO2003101992A1 (US07786301-20100831-C00009.png)
ZA (1) ZA200408719B (US07786301-20100831-C00009.png)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
US7407955B2 (en) 2002-08-21 2008-08-05 Boehringer Ingelheim Pharma Gmbh & Co., Kg 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
US7495005B2 (en) * 2002-08-22 2009-02-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, their preparation and their use in pharmaceutical compositions
US7569574B2 (en) 2002-08-22 2009-08-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
US7482337B2 (en) 2002-11-08 2009-01-27 Boehringer Ingelheim Pharma Gmbh & Co. Kg Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
DE10254304A1 (de) * 2002-11-21 2004-06-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
US7566707B2 (en) * 2003-06-18 2009-07-28 Boehringer Ingelheim International Gmbh Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
CA2533715A1 (en) 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
AR047948A1 (es) * 2003-11-21 2006-03-15 Schering Corp Formulaciuones de inhibidores de la fosfodiesterasa v
DE10355304A1 (de) 2003-11-27 2005-06-23 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
US7501426B2 (en) * 2004-02-18 2009-03-10 Boehringer Ingelheim International Gmbh 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
DE102004009039A1 (de) * 2004-02-23 2005-09-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
US7393847B2 (en) 2004-03-13 2008-07-01 Boehringer Ingleheim International Gmbh Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
US7179809B2 (en) * 2004-04-10 2007-02-20 Boehringer Ingelheim International Gmbh 2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
US7439370B2 (en) * 2004-05-10 2008-10-21 Boehringer Ingelheim International Gmbh Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
DE102004030502A1 (de) * 2004-06-24 2006-01-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
DE102004043944A1 (de) * 2004-09-11 2006-03-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004044221A1 (de) * 2004-09-14 2006-03-16 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
DE102004054054A1 (de) * 2004-11-05 2006-05-11 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
EP1852108A1 (en) 2006-05-04 2007-11-07 Boehringer Ingelheim Pharma GmbH & Co.KG DPP IV inhibitor formulations
EA030606B1 (ru) 2006-05-04 2018-08-31 Бёрингер Ингельхайм Интернациональ Гмбх Способы приготовления лекарственного средства, содержащего полиморфы
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
EP2057160A1 (en) 2006-08-08 2009-05-13 Boehringer Ingelheim International GmbH Pyrrolo [3, 2 -d]pyrimidines as dpp-iv inhibitors for the treatment of diabetes mellitus
KR101610005B1 (ko) * 2007-08-17 2016-04-08 베링거 인겔하임 인터내셔날 게엠베하 Ｆａｂ 관련 질환의 치료에 사용하기 위한 푸린 유도체
PE20140960A1 (es) 2008-04-03 2014-08-15 Boehringer Ingelheim Int Formulaciones que comprenden un inhibidor de dpp4
PE20100156A1 (es) * 2008-06-03 2010-02-23 Boehringer Ingelheim Int Tratamiento de nafld
BRPI0916997A2 (pt) 2008-08-06 2020-12-15 Boehringer Ingelheim International Gmbh Inibidor de dpp-4 e seu uso
UY32030A (es) 2008-08-06 2010-03-26 Boehringer Ingelheim Int "tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
EA031225B1 (ru) * 2008-08-15 2018-12-28 Бёрингер Ингельхайм Интернациональ Гмбх Ингибиторы дпп-4 для заживления ран
EP2344195A2 (en) 2008-09-10 2011-07-20 Boehringer Ingelheim International GmbH Combination therapy for the treatment of diabetes and related conditions
US20200155558A1 (en) 2018-11-20 2020-05-21 Boehringer Ingelheim International Gmbh Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug
BRPI0923121A2 (pt) 2008-12-23 2015-08-11 Boehringer Ingelheim Int Formas salinas de compostos orgânico
TW201036975A (en) 2009-01-07 2010-10-16 Boehringer Ingelheim Int Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
ES2760917T3 (es) 2009-11-27 2020-05-18 Boehringer Ingelheim Int Tratamiento de pacientes diabéticos genotipificados con inhibidores DPP-IV como la linagliptina
JP6034781B2 (ja) 2010-05-05 2016-11-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 併用療法
EA201991014A1 (ru) 2010-06-24 2019-09-30 Бёрингер Ингельхайм Интернациональ Гмбх Лечение диабета
US9034883B2 (en) 2010-11-15 2015-05-19 Boehringer Ingelheim International Gmbh Vasoprotective and cardioprotective antidiabetic therapy
MX366629B (es) 2011-07-15 2019-07-17 Boehringer Ingelheim Int Quinazolinas sustituidas, su preparación y su uso en composiciones farmacéuticas.
US9555001B2 (en) 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
EP3685839A1 (en) 2012-05-14 2020-07-29 Boehringer Ingelheim International GmbH Linagliptin for use in the treatment of albuminuria and kidney related diseases
WO2013174767A1 (en) 2012-05-24 2013-11-28 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
US9526728B2 (en) 2014-02-28 2016-12-27 Boehringer Ingelheim International Gmbh Medical use of a DPP-4 inhibitor
JP2019517542A (ja) 2016-06-10 2019-06-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング リナグリプチンおよびメトホルミンの組合せ

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6903224B2 (en) * 1988-04-11 2005-06-07 Biochem Pharma Inc. Substituted 1,3-oxathiolanes
US5064825A (en) * 1989-06-01 1991-11-12 Merck & Co., Inc. Angiotensin ii antagonists
JPH0372480A (ja) * 1989-08-10 1991-03-27 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びそれらを有効成分とする気管支拡張剤
CA2030112A1 (en) * 1989-11-24 1991-05-25 Yasuo Ito Xanthine compound, method for preparing thereof, and a pharmaceutical composition comprising the same
IL98559A0 (en) * 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
JPH04128285A (ja) * 1990-06-27 1992-04-28 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH04279586A (ja) * 1991-03-05 1992-10-05 Hokuriku Seiyaku Co Ltd キサンチン誘導体
JPH051065A (ja) * 1991-06-20 1993-01-08 Hokuriku Seiyaku Co Ltd キサンチン誘導体
DE59208572D1 (de) * 1991-10-17 1997-07-10 Ciba Geigy Ag Bicyclische Nukleoside, Oligonukleotide, Verfahren zu deren Herstellung und Zwischenprodukte
DE4411660A1 (de) * 1994-04-05 1995-10-12 Hoechst Ag Verwendung von Xanthinderivaten zur Reduktion der pathologischen Hyperreagibilität eosinophiler Granulozyten, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel
ATE226583T1 (de) * 1996-06-07 2002-11-15 Hoechst Ag Verwendung von theophyllinderivaten zur behandlung und propylaxe von schockzuständen, neue xanthinverbindungen und verfahren zu deren herstellung
HUP0301622A3 (en) * 2000-07-04 2006-05-29 Novo Nordisk As Purine derivatives inhibiting the enzyme dipeptidyl petidase iv (dpp-iv) and pharmaceutical compositions containing them
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
NZ528216A (en) * 2001-02-24 2006-12-22 Boehringer Ingelheim Pharma Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
US6869947B2 (en) * 2001-07-03 2005-03-22 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
EP1421084B1 (en) 2001-08-28 2008-05-14 Schering Corporation Polycyclic guanine phosphodiesterase v inhibitors
EP1463727A2 (en) * 2001-09-19 2004-10-06 Novo Nordisk A/S Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
EP1442042A1 (en) 2001-11-09 2004-08-04 Schering Corporation Polycyclic guanine derivative phosphodiesterase v inhibitors
ATE409466T1 (de) * 2002-01-11 2008-10-15 Novo Nordisk As Verfahren und zusammensetzung zur behandlung von diabetes, hypertonie, chronischer herzinsuffizienz und mit flüssigkeitsretention einhergehenden zuständen
JP2004043429A (ja) * 2002-02-25 2004-02-12 Eisai Co Ltd 新規キサンチン誘導体およびｄｐｐｉｖ阻害剤
TW200404802A (en) * 2002-05-31 2004-04-01 Schering Corp Xanthine phosphodiesterase V inhibitor polymorphs
WO2004009091A1 (en) * 2002-06-17 2004-01-29 Glaxo Group Limited Purine derivatives as liver x receptor agonists
KR101150449B1 (ko) * 2002-08-21 2012-06-01 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 8-［3-아미노-피페리딘-1-일］-크산틴, 이의 제조방법 및 이를 포함하는 약제학적 조성물
AU2003269850A1 (en) * 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
AU2003280680A1 (en) * 2002-11-01 2004-06-18 Sumitomo Pharmaceuticals Co., Ltd. Xanthine compound
US7247639B2 (en) * 2003-06-06 2007-07-24 Endacea, Inc. A1 adenosine receptor antagonists
CA2533715A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
DE102005035891A1 (de) * 2005-07-30 2007-02-08 Boehringer Ingelheim Pharma Gmbh & Co. Kg 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
US7074923B2 (en) 2006-07-11
CN100497336C (zh) 2009-06-10
CN1668618A (zh) 2005-09-14
DE60307628D1 (de) 2006-09-28
US20030232987A1 (en) 2003-12-18
CN101538224A (zh) 2009-09-23
WO2003101992A1 (en) 2003-12-11
EP1509525B1 (en) 2006-08-16
DK1509525T5 (da) 2007-07-30
AR040232A1 (es) 2005-03-23
EP1509525B9 (en) 2007-10-31
PT1509525E (pt) 2006-12-29
HK1068139A1 (en) 2005-04-22
JP2005529934A (ja) 2005-10-06
MXPA04011862A (es) 2005-03-31
ZA200408719B (en) 2005-11-15
CY1105774T1 (el) 2011-02-02
CA2483923A1 (en) 2003-12-11
EP1509525A1 (en) 2005-03-02
ES2270047T3 (es) 2007-04-01
DK1509525T3 (da) 2006-12-11
DE60307628T2 (de) 2007-08-09
US20060205943A1 (en) 2006-09-14
ATE336494T1 (de) 2006-09-15
US7786301B2 (en) 2010-08-31

Similar Documents

Publication Publication Date Title
AU2003238822A1 (en) Process for preparing xanthine phosphodiesterase v inhibitors and precursors thereof
AU2003270785A1 (en) Process for preparing quinazoline rho-kinase inhibitors and intermediates thereof
AU9102201A (en) Xanthine phosphodiesterase v inhibitors
IL165849A0 (en) Process for preparing pyrimidine derivatives novelpyrimidine derivatives and pharmaceutical composi tions containing the same
AP2064A (en) Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors
IL167088A (en) Pyrazolopyrimidine derivatives as cyclin dependent kinase inhibitors
AU2003259749A1 (en) 3-pyrrolyl-pyridopyrazoles and 3-pyrrolyl-indazoles as novel kinase inhibitors
AU2003222055A1 (en) Kinase inhibitors
HK1089448A1 (en) Process for preparing inhibitors of nucleoside phosphorylases and nucleosidases
HUP0500851A3 (en) Process for the preparation of rosuvastatin
HK1068140A1 (en) Xanthine phosphodiesterase v inhibitor polymorphs
EP1590335A4 (en) PROCESS FOR THE PRODUCTION OF PYRROLOTRIAZINKINASE INHIBITORS
AU2003260945A1 (en) Methods of use for thermostable rna ligases
AU2003302588A1 (en) Phosphodiesterase 10a inhibitors
AU2003210983A1 (en) Kinase inhibitors and methods of use thereof
AU2003244080A1 (en) Phosphodiesterase inhibitor
AU2003269561A1 (en) Method for preparing risperidone
AU2003298978A1 (en) Process for finishing the surface of an article and article thus obtained
SI1509525T1 (sl) Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
AUPS251402A0 (en) Kinase inhibitors
AU2003256006A1 (en) Improved process for preparation of risperidone
AU2003213281A1 (en) Process and intermediates for preparing phenylthiomethyl-thiazoles or oxazoles
AU2002317788A1 (en) Imidazotriazines for use as phosphodiesterase inhibitors
AU2003285600A1 (en) Process for the preparing ziprasidone monohydrochloride hydrate
AU2003210296A8 (en) Process for the preparation of 4-hetero-substituted phenylalanine derivatives

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase